Mochida Pharmaceutical Co., Ltd. · TSE:4534
Mochida Pharmaceutical — FY2025 Earnings Presentation
32 slides from Mochida Pharmaceutical's earnings presentation, May 21, 2026
Slide 1: FY2025 Financial Results Presentation
FY2025 Financial Results Presentation (Fiscal Year Ended March 31, 2026) May 21, 2026 Mochida Pharmaceutical Co., Ltd.
Slide 2: Agenda
Agenda • FY2025 Overview • FY2026 Forecast • Progress on the Development • Progress on the 25-27 Medium-term Management Plan FY2025 Financial Results Presentation 2
Slide 3: FY2025 Overview
FY2025 Overview FY2025 Financial Results Presentation 3
Slide 4: Summary of FY2025
Summary of FY2025 ◼ Consolidated Financial Results Increase in Net sales Increase in Operating profit ✓ Net sales increased due to the growth of new drugs ✓ Operating profit increased due to an increase in gross profit and healthcare products. resulting from higher net sales in the pharmaceutical bu
Slide 5: Consolidated Operating Results in FY2025
Consolidated Operating Results in FY2025 (Millions of yen) FY2025 Forecast FY2024 FY2025 YoY change (announced on May 12, 2025) (YoY change) (YoY change) (YoY change) 105,159 116,951 110,500 Net sales 11,791 (2.2%) (11.2%) (5.1%) 8,126 10,147 7,000 Operating profit 2,021 (40.1%) (24.9%) (-13.9%) Rat
Slide 6: Net Sales by Business in FY2025
Net Sales by Business in FY2025 (Millions of yen) FY2025 Forecast FY2024 FY2025 YoY change (announced on May 12, 2025) (Billions of yen) (YoY change) (YoY change) (YoY change) 105,159 116,951 110,500 7.9 Net sales 11,791 (2.2%) (11.2%) (5.1%) 7.1 Pharmaceutical 97,989 109,042 103,000 business 11,052
Slide 7: Sales of Major Products in FY2025 (1/2)
Sales of Major Products in FY2025 (1/2) (Billions of yen) FY2025 Products FY2024 YoY Sales Value Ratio ■ New drugs Treatment of ulcerative colitis Lialda 15.1 16.8 1.7 11% Treatment for chronic constipation Goofice 8.3 9.0 0.7 8% Treatment for chronic constipation Movicol 6.6 7.1 0.5 8% Treatment fo
Slide 8: Sales of Major Products in FY2025 (2/2)
Sales of Major Products in FY2025 (2/2) (Billions of yen) FY2025 Products FY2024 YoY Sales Value Ratio ■ Long-listed products Drug for hyperlipidemia and arteriosclerosis obliterans Epadel 4.8 4.6 -0.2 -5% Heparin Anticoagulant agent Sodium 1.3 1.4 0 5% MOCHIDA ■ Generic drugs (including biosimilars
Slide 9: Consolidated Financial Statements
Consolidated Financial Statements (Millions of yen) FY2024 FY2025 YoY YoY Major fluctuation factors (As of March 31, 2025) (As of March 31, 2026) change change Total assets 160,121 182,720 22,599 Cash and deposits -17,089 Securities -3,002 Total current Accounts receivable - trade, and contract asse
Slide 10: Cash Dividends
Cash Dividends ⚫ Based on our basic policy of maintaining stable dividends, we intend to Shareholder maintain a dividend of at least 80 yen per share during the 25–27 Medium- Returns term Management Plan period. Policy ⚫ We will flexibly respond to changes in the business environment with respect to
Slide 11: FY2026 Forecast
FY2026 Forecast FY2025 Financial Results Presentation 11
Slide 12: Prospects for FY2026 (1/3)
Prospects for FY2026 (1/3) ◼ Consolidated Financial Forecast Increase in Net sales Increase in Operating profit ✓ Net sales will increase, driven by new drugs in the ✓ Operating profit will increase due to higher net sales. pharmaceutical business. ✓ Ordinary profit will be supported by equity in ea
Slide 13: Prospects for FY2026 (2/3)
Prospects for FY2026 (2/3) Pharmaceutical Business ⚫ Maximizing the product value of five major new drugs ✓ Enhancing the value penetration of Omvoh and Cortiment through a focus on the gastroenterology ✓ Further expanding Urece, Goofice, and Treprost ⚫ Further value enhancement of flagship drugs ✓
Slide 14: Prospects for FY2026 (3/3)
Prospects for FY2026 (3/3) Biomaterials Business ⚫ Accelerating the expansion of Cartilage repair device Mochi-Gel through a strengthened value proposition ⚫ Pursuing partnerships with sales distributors in the U.S. and expanding ReFeel. ⚫ Advancing clinical trials of dMD-002 for cavernous nerve inj
Slide 15: Consolidated Financial Result Forecast in FY2026
Consolidated Financial Result Forecast in FY2026 (Millions of yen) FY2024 FY2025 FY2026 Forecast (YoY change) (YoY change) (YoY change) 105,159 116,951 126,000 Net sales (2.2%) (11.2%) (7.7%) 8,126 10,147 10,500 Operating profit (40.1%) (24.9%) (3.5%) Ratio of operating 7.7％ 8.7% 8.3% profit to net
Slide 16: Forecast by Business in FY2026
Forecast by Business in FY2026 (Millions of yen) FY2024 FY2025 FY2026 Forecast (YoY change) (YoY change) (YoY change) 105,159 116,951 126,000 Net sales (2.2%) (11.2%) (7.7%) Pharmaceutical 97,989 109,042 117,700 business (1.6%) (11.3%) (7.9%) Healthcare 7,169 7,908 8,300 business (11.5%) (10.3%) (5.
Slide 17: Forecast of Major Products in FY2026 (1/2)
Forecast of Major Products in FY2026 (1/2) (Billions of yen) FY2026 Forecasts Products FY2025 YoY change Sales Value Ratio ■ New drugs Treatment of ulcerative colitis Lialda 16.8 17.4 0.5 4% Treatment for chronic constipation Goofice 9.0 9.7 0.6 7% Treatment for chronic constipation Movicol *1 7.1 1
Slide 18: Forecast of Major Products in FY2026 (2/2)
Forecast of Major Products in FY2026 (2/2) (Billions of yen) FY2026 Forecasts Products FY2025 YoY change Sales Value Ratio ■ Long-listed products Drug for hyperlipidemia and arteriosclerosis obliterans Epadel 4.6 5.3 0.7 17% Heparin Anticoagulant agent Sodium 1.4 1.7 0.2 19% MOCHIDA ■ Generic drugs
Slide 19: Forecast of Cash Dividends in FY2026
Forecast of Cash Dividends in FY2026 ⚫ Based on our basic policy of maintaining stable dividends, we intend to Shareholder maintain a dividend of at least 80 yen per share during the 25–27 Medium- Returns term Management Plan period. Policy ⚫ We will flexibly respond to changes in the business envir
Slide 20: Progress on the Development
Progress on the Development FY2025 Financial Results Presentation 20
Slide 21: Development Pipeline of Ethical drugs
Development Pipeline of Ethical drugs Development code Stage Remarks Indications <Generic name> Phase Ⅱ Phase Ⅲ Filed Approved <Development country> Biosimilar RGB-19 *1 Rheumatoid Arthritis, etc. Approved Licensed-in from Gedeon Richter Plc. <tocilizumab> <Japan> Licensed-in from United Therapeutic
Slide 22: Development Pipeline of Medical devices
Development Pipeline of Medical devices Stage Intended use Therapeutic Therapeutic Remarks Development code or indications exploratory confirmatory Filed Approved ＜Development country＞ study study Therapeutic In-house development dMD-002 Repair of cavernous nerve injury confirmatory <Japan> Preventi
Slide 23: Progress on the 25-27 Medium-term Management Plan
Progress on the 25-27 Medium-term Management Plan FY2025 Financial Results Presentation 23
Slide 24: Roadmap for the realization of Vision for 2031
Roadmap for the realization of Vision for 2031 Positioning toward Vision for 2031: Medium-term Management Plan - Laying the Foundation in FY2022- 2024 and Accelerating Growth Strategy in FY2025-2027. FY2022‐2024 Laying the Foundation FY2025‐2027 Accelerating Acceleration FY2028‐2030 Achievement of V
Slide 25: Overview of Growth Strategy Acceleration
Overview of Growth Strategy Acceleration Under the 25–27 Medium-term Management Plan, three key themes to accelerate the growth strategy have been established, and Medium- term Management Plan KPIs (MTP KPIs) have been set. Continued Investment Strengthening the Profitability in Growth Businesses of
Slide 26: Progress on KGI
Progress on KGI (Billions of yen) 25-27 Medium-term Management Plan KGI * FY2024 FY2031 FY2026 FY2027 FY2025 Forecasts Forecasts Net sales 105.1 116.9 126.0 120.0 140.0 Operating profit 8.1 10.1 10.5 12.0 21.0 EBITDA ＋R&D expenses 22.7 25.2 29.4 26.5 35.5 * KGI: Key Goal Indicator FY2025 Financial R
Slide 27: Strengthening the Profitability of Core Businesses
Strengthening the Profitability of Core Businesses MTP KPIs *1 FY2025 Results ⚫ Net sales of five major new ⚫ Net sales of five major new drugs: 32.9 billion yen drugs: 48.0 billion yen New drugs ⚫ One in-licensed item ⚫ Three in-licensed items ✓ Bonjesta for the treatment of nausea and Pharmaceutic
Slide 28: Continued Investment in Growth Businesses
Continued Investment in Growth Businesses MTP KPIs * FY2025 Results 【Japan】 ⚫ Launch of Cartilage repair device Mochi-Gel ⚫ Initiation of a therapeutic confirmatory study for Biomaterials ⚫ Launch of at least five products dMD-002 business ⚫ Net sales: 2.6 billion yen 【U.S.】 ⚫ Establishment of Mochi
Slide 29: Financial Strategy (Cash Allocation)
Financial Strategy（Cash Allocation） 25-27 Medium-term Management Plan FY2025 Results Cash Allocation Research Research and ⚫ Active investment to expand the Resources during the and A total of 36.0 billion development pipeline (adding one new drug and 25-27 Medium-term development yen over three yea
Slide 30: FY2025 Financial Results Presentation
FY2025 Financial Results Presentation 30
Slide 31: Disclaimer (1/2)
Disclaimer (1/2) ◼ This material is an English translation of the Financial Results Presentation for the Fiscal Year 2025 to be issued on May 21, 2026 in Japanese, and the Japanese presentation is given priority regarding content and interpretation. ◼ The information provided in this material contai
Slide 32: Disclaimer (2/2)
Disclaimer (2/2) ◼ Approved products contain risks relating to manufacturing and marketing which include, but are not limited to, situations in which the Company may face deficiencies in manufacturing capacity needed to meet demand, difficulties in securing the supplies of raw materials, and demand
Mochida Pharmaceutical — FY2025 Earnings Presentation on 6ix